⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNGX News
Tango Therapeutics, Inc.
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
globenewswire.com
TNGX
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
TNGX
Form 8-K
sec.gov
TNGX
Form 8-K
sec.gov
TNGX
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
globenewswire.com
TNGX
Form 8-K
sec.gov
TNGX
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
TNGX
Form 8-K
sec.gov
TNGX
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
globenewswire.com
TNGX
RMD
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
globenewswire.com
ATOS
ONCY
SNSE
TNGX
OSTX